Philadelphia chromosome-positive B cell acute lymphoblastic leukemia (B-ALL), characterized by the <i>BCR::ABL1</i> fusion gene, remains a poor prognosis cancer needing new therapeutic approaches. This evidence concerns the gene ABL1 and B-cell acute lymphoblastic leukemia.